Immix Biopharma annual r&d spending
2020
2021
2022
2023
2024
2025
Immix Biopharma R&D Spending Growth & History (IMMX)
Immix Biopharma's r&d spending was $16.3M for fiscal 2025.
View full Immix Biopharma company overviewImmix Biopharma annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $16.3M | $5.0M | +43.97% |
| 2024 | 2024-12-31 | $11.3M | $2.6M | +29.28% |
| 2023 | 2023-12-31 | $8.7M | $4.5M | +108.19% |
| 2022 | 2022-12-31 | $4.2M | $4.1M | +3216.11% |
| 2021 | 2021-12-31 | $126,527 | −$121,622 | −49.01% |
| 2020 | 2020-12-31 | $248,149 | — | — |
Immix Biopharma quarterly r&d spending
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $5.3M | $1.4M | +34.25% |
| Q1 2026 | 2026-03-31 | $6.0M | $4.0M | +202.80% |
| Q4 2025 | 2025-12-31 | $5.7M | $4.4M | +316.70% |
| Q3 2025 | 2025-09-30 | $4.6M | $138,603 | +3.12% |
| Q2 2025 | 2025-06-30 | $4.0M | $1.7M | +78.61% |
| Q1 2025 | 2025-03-31 | $2.0M | −$1.3M | −39.20% |
| Q4 2024 | 2024-12-31 | $1.4M | −$1.7M | −55.68% |
| Q3 2024 | 2024-09-30 | $4.4M | $2.3M | +111.09% |
| Q2 2024 | 2024-06-30 | $2.2M | $14,895 | +0.67% |
| Q1 2024 | 2024-03-31 | $3.2M | $1.9M | +146.29% |
| Q4 2023 | 2023-12-31 | $3.1M | $838,188 | +37.05% |
| Q3 2023 | 2023-09-30 | $2.1M | $1.4M | +202.62% |
| Q2 2023 | 2023-06-30 | $2.2M | $1.6M | +263.51% |
| Q1 2023 | 2023-03-31 | $1.3M | $689,489 | +109.52% |
| Q4 2022 | 2022-12-31 | $2.3M | $2.3M | +24397.17% |
| Q3 2022 | 2022-09-30 | $695,937 | $666,247 | +2244.01% |
| Q2 2022 | 2022-06-30 | $607,751 | $544,990 | +868.36% |
| Q1 2022 | 2022-03-31 | $629,531 | $604,691 | +2434.34% |
| Q4 2021 | 2021-12-31 | $9,236 | — | — |
| Q3 2021 | 2021-09-30 | $29,690 | — | — |
| Q2 2021 | 2021-06-30 | $62,761 | — | — |
| Q1 2021 | 2021-03-31 | $24,840 | — | — |
Immix Biopharma r&d spending trends
Over the last five fiscal years, Immix Biopharma's r&d spending increased from $248,149 to $16.3M, a change of $16.0M. The latest reported quarter, Q2 2026, shows $5.3M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Immix Biopharma source filings ↗